Research Progress of Zolbetuximab in the Treatment of Gastric Cancer
Gastric cancer is one of the common malignant tumors in the digestive system.For pa-tients with microsatellite instability/mismatch repair defects,human epidermal growth factor re-ceptor 2 and PD-L1 positive gastric cancer,although immunotherapy and targeted therapy have made some progress,the survival rate is still low.The CLDN18.2 of the Claudin proteins(Claudins)family is present in various tumor tissues and is closely related to the occurrence and progression of tumors.Its expression is specific in gastric cancer and its metastases.This paper focuses on the research progress of CLDN18.2 monoclonal antibody Zolbetuximab in the treatment of gastric cancer.
NETL
NSTL
万方数据
